US Patent No: 7,749,542

Number of patents in Portfolio can not be more than 2000

Opioid agonist/antagonist combinations

ALSO PUBLISHED AS: 20080292694
1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
PURDUE PHARMA L.P.STAMFORD, CT265

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Colucci, Robert D Newtown, CT 22 629
Kaiko, Robert F Weston, CT 45 1065

Cited Art Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (39)
4,828,836 Controlled release pharmaceutical composition 155 1987
4,834,985 Controlled release pharmaceutical composition 179 1987
4,990,341 Controlled release hydromorphone composition 103 1989
5,266,331 Controlled release oxycodone compositions 116 1991
5,273,760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 157 1991
5,286,493 Stabilized controlled release formulations having acrylic polymer coating 154 1992
5,549,912 Controlled release oxycodone compositions 108 1993
5,472,712 Controlled-release formulations coated with aqueous dispersions of ethylcellulose 136 1993
5,478,577 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level 121 1993
5,411,745 Powder-layered morphine sulfate formulations 81 1994
5,965,161 Extruded multi-particulates 91 1994
5,639,476 Controlled release formulations coated with aqueous dispersions of acrylic polymers 317 1995
5,508,042 Controlled release oxycodone compositions 112 1995
5,968,551 Orally administrable opioid formulations having extended duration of effect 125 1995
5,958,459 Opioid formulations having extended controlled released 76 1995
5,656,295 Controlled release oxycodone compositions 95 1996
5,681,585 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 76 1996
5,672,360 Method of treating pain by administering 24 hour oral opioid formulations 122 1996
6,143,322 Method of treating humans with opioid formulations having extended controlled release 87 1997
5,958,452 Extruded orally administrable opioid formulations 111 1997
5,968,547 Method of providing sustained analgesia with buprenorphine 67 1997
6,077,533 Powder-layered oral dosage forms 50 1998
6,228,863 Method of preventing abuse of opioid dosage forms 103 1998
6,277,384 Opioid agonist/antagonist combinations 76 1998
6,103,261 Opioid formulations having extended controlled release 81 1999
6,335,033 Melt-extrusion multiparticulates 59 1999
6,261,599 Melt-extruded orally administrable opioid formulations 92 1999
6,294,195 Orally administrable opioid formulations having extended duration of effect 86 1999
6,375,957 Opioid agonist/opioid antagonist/acetaminophen combinations 96 2000
6,696,088 Tamper-resistant oral opioid agonist formulations 81 2001
6,475,494 Opioid agonist/antagonist combinations 57 2001
2003/0069,263 Pharmaceutical combinations of oxycodone and naloxone 38 2002
2003/0073,714 Opioid agonist formulations with releasable and sequestered antagonist 37 2002
6,696,066 Opioid agonist/antagonist combinations 71 2002
2003/0229,111 Naltrexone hydrochloride compositions 12 2003
2004/0186,121 Tamper-resistant oral opioid agonist formulations 30 2003
7,172,767 Opioid agonist / antagonist combinations 37 2003
2006/0182,801 Sequestered antagonist formulations 29 2006
7,419,686 Opioid agonist/antagonist combinations 18 2006
 
EURO-CELTIQUE S.A. (35)
4,366,310 Controlled release compositions 40 1980
4,940,587 Oral pharmaceutical composition through mucosa 93 1986
4,844,907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 114 1986
4,834,965 Controlled release pharmaceutical composition 70 1987
4,867,985 Spheroids 75 1988
5,071,646 Pharmaceutical ion exchange resin composition 95 1989
5,091,189 Controlled release dosage forms having a defined water content 35 1991
5,215,758 Controlled release matrix suppository for pharmaceuticals 69 1991
5,324,351 Aqueous dispersions of zein and preparation thereof 78 1992
5,356,467 Controlled release coatings derived from aqueous dispersions of zein 117 1993
5,500,227 Immediate release tablet cores of insoluble drugs having sustained-release coating 120 1993
5,622,722 Spheroid formulation 34 1994
5,508,043 Controlled release matrix for pharmaceuticals 42 1995
5,670,172 Pharmaceutical spheroid formulation 58 1995
6,024,982 Immediate release tablet cores of insoluble drugs having sustained-release coating 78 1995
5,811,126 Controlled release matrix for pharmaceuticals 63 1995
5,763,452 Pharmaceutical compositions and usages 33 1996
5,849,240 Method of preparing sustained release pharmaceutical compositions 83 1996
5,891,471 Pharmaceutical multiparticulates 77 1996
5,601,845 Pharmaceutical spheroid formulation 70 1996
5,843,480 Controlled release diamorphine formulation 60 1996
5,879,705 Sustained release compositions of morphine and a method of preparing pharmaceutical compositions 78 1997
5,908,848 Synergistic composition of codine and ibuprofen to treat arthritis 35 1997
5,942,241 Formulations and methods for providing prolonged local anesthesia 102 1997
6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same 54 1997
5,965,163 Substained release compositions and a method of preparing pharmaceutical compositions 86 1997
6,077,532 Pharmaceutical ion exchange resin composition 40 1998
6,306,438 Stabilized sustained release tramadol formulations 52 1998
6,399,096 Pharmaceutical formulation 48 1998
6,143,328 Sustained release compositions and a method of preparing pharmaceutical compositions 41 1999
6,162,467 Sustained release compositions and a method of preparing pharmaceutical compositions 61 1999
6,210,714 Immediate release tablet cores of acetaminophen having sustained-release coating 55 2000
6,387,404 Immediate release tablet cores of insoluble drugs having sustained-release coating 56 2001
6,716,449 Controlled-release compositions containing opioid agonist and antagonist 59 2001
6,627,635 Method of preventing abuse of opioid dosage forms 69 2001
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (12)
5,472,943 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists 72 1993
5,585,348 Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia 61 1993
5,512,578 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists 81 1994
5,624,932 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 39 1995
5,580,876 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 64 1995
5,767,125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 66 1996
6,096,756 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 63 1998
6,194,382 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 39 1999
2001/0006,967 METHOD OF SIMULTANEOUSLY ENHANCING ANALGESIC POTENCY AND ATTENUATING ADVERSE SIDE EFFECTS CAUSED BY TRAMADOL AND OTHER BIMODALLY-ACTING OPIOID AGONISTS 14 1999
6,362,194 Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 28 2000
6,395,705 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 36 2001
6,765,010 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects 29 2002
 
MERCK FROSST CANADA LTD. (10)
5,409,944 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase 61 1993
5,604,260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 73 1993
5,436,265 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents 74 1993
5,521,213 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 84 1994
5,552,422 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents 90 1995
5,536,752 Phenyl heterocycles as COX-2 inhibitors 69 1995
5,550,142 Phenyl heterocycles as cox-2 inhibitors 75 1995
5,510,368 N-benzyl-3-indoleacetic acids as antiinflammatory drugs 78 1995
5,604,253 N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors 62 1995
5,639,780 N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors 60 1995
 
ALZA CORPORATION (6)
4,200,098 Osmotic system with distribution zone for dispensing beneficial agent 304 1978
4,285,987 Process for manufacturing device with dispersion zone 272 1979
4,573,995 Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine 125 1984
5,236,714 Abusable substance dosage form having reduced abuse potential 82 1988
5,460,826 Morphine therapy 81 1994
5,866,164 Composition and dosage form comprising opioid antagonist 97 1997
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (6)
4,401,672 Non-addictive narcotic antitussive preparation 51 1981
4,730,048 Gut-selective opiates 69 1985
5,352,680 Delta opioid receptor antagonists to block opioid agonist tolerance and dependence 88 1992
5,457,208 Kappa opioid receptor antagonists 63 1993
5,578,725 Delta opioid receptor antagonists 46 1995
5,780,479 Use of opioid antagonists to treat impulse-control disorders 43 1997
 
UNIVERSITY OF CHICAGO, THE (4)
4,719,215 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 72 1986
4,861,781 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 67 1987
5,102,887 Method for reducing emesis and nausea induced by the administration of an emesis causing agent 68 1990
5,972,954 Use of methylnaltrexone and related compounds 80 1997
 
VIRGINIA COMMONWEALTH UNIVERSITY (4)
5,352,683 Method for the treatment of chronic pain 71 1993
5,321,012 Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance 109 1993
5,502,058 Method for the treatment of pain 92 1994
5,556,838 Inhibiting the development of tolerance to and/or dependence on an addictive substance 103 1994
 
CONTRAL CLINICS OY (3)
4,882,335 Method for treating alcohol-drinking response 64 1988
5,096,715 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist 49 1989
5,086,058 Method for treating alcoholism with nalmefene 62 1990
 
NAPP PHARMACEUTICAL GROUP LIMITED (3)
5,591,452 Controlled release formulation 73 1994
6,326,027 Controlled release formulation 62 1995
6,254,887 Controlled release tramadol 57 1996
 
The Rockefeller University (3)
4,987,136 Method for controlling gastrointestinal dysmotility 100 1986
4,769,372 Method of treating patients suffering from chronic pain or chronic cough 74 1986
4,785,000 Method of treating patients suffering from chronic pain or chronic cough 52 1987
 
BASF AKTIENGESELLSCHAFT (2)
4,806,558 Diarylacetylenes and their use in treating acne 44 1985
4,957,681 Preparation of pharmaceutical mixtures 80 1989
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
4,451,470 Analgesic, antagonist, and/or anorectic 14-fluoromorphinans 52 1982
5,593,994 Prostaglandin synthase inhibitors 56 1994
 
Eli Lilly and Company (2)
4,293,539 Controlled release formulations and method of treatment 89 1979
5,998,434 Composition for treating pain 37 1998
 
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURG (2)
4,844,909 Controlled release hydromorphone composition 97 1987
4,844,910 Spheroids 43 1987
 
NOVA PHARMACEUTICAL CORPORATION (2)
4,760,069 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 55 1985
4,889,860 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 59 1987
 
OMEROS CORPORATION (2)
5,858,017 Urologic irrigation solution and method for inhibition of pain, inflammation and spasm 96 1996
5,860,950 Arthroscopic irrigation solution and method for inhibition of pain and inflammation 82 1996
 
PURDUE PHARMA COMPANY, THE (2)
4,861,598 Controlled release bases for pharmaceuticals 118 1986
4,970,075 Controlled release bases for pharmaceuticals 96 1989
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (2)
4,582,835 Analgesic compositions 90 1984
4,661,492 Analgesic compositions 61 1985
 
Schaap; Robert J. (2)
5,316,759 Agonist-antagonist combination to reduce the use of nicotine and other drugs 57 1992
5,574,052 Agonist-antagonist combination to reduce the use of nicotine and other drugs 106 1994
 
ADIR ET COMPAGNIE (1)
5,130,311 Oxazolopyridine compounds, compositions and use 40 1991
 
Aminotek Sciences, Inc. (1)
5,256,669 Methods and compositions for treating acute or chronic pain and drug addiction 50 1992
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
4,873,076 Method of safely providing anesthesia or conscious sedation 51 1989
 
BRISTOL-MYERS SQUIBB COMPANY (1)
4,457,933 Prevention of analgesic abuse 87 1981
 
COLMAN PRODUCTS LIMITED (1)
4,935,428 Treating opiate dependence 62 1988
 
DUPONT MERCK PHARMACEUTICAL COMPANY, THE (1)
4,722,928 N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes 18 1985
 
DUPONT PHARMACEUTICALS COMPANY (1)
4,237,140 Analgesic mixture of nalbuphine and acetaminophen 48 1979
 
DYNAGEN, INC. (1)
5,486,362 Controlled, sustained release delivery system for treating drug dependency 86 1993
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (1)
5,869,097 Method of therapy comprising an osmotic caplet 52 1992
 
G. D. Searle & Co. (1)
5,616,601 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation 108 1995
 
GENERAL ELECTRIC COMPANY (1)
5,226,331 Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream 38 1991
 
ICN HUNGARY RT. (1)
5,317,022 Pharmaceutical composition and use 49 1992
 
LIFESHIELD SCIENCES LLC (1)
2004/0158,312 Braided endoluminal device having tapered filaments 4 2003
 
McGinnis; Carolyn (1)
4,608,376 Opiate agonists and antagonists 42 1982
 
MERCK FROSST COMPANY (1)
5,474,995 Phenyl heterocycles as cox-2 inhibitors 143 1994
 
MERCK SHARP & DOHME LTD. (1)
5,880,132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception 49 1997
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
5,225,440 Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase 48 1991
 
OREGON, UNIVERSITY OF (1)
5,514,680 Glycine receptor antagonists and the use thereof 57 1993
 
ORTHO-MCNEIL PHARMACEUTICAL, INC. (1)
5,336,691 Composition comprising a tramadol material and acetaminophen and its use 60 1992
 
PEPTECH LIMITED (1)
5,534,492 Muramyl peptide for the treatment of toxicity 39 1995
 
PUREUE PHARMA L.P. (1)
4,834,984 Controlled release dihydrocodeine composition 92 1987
 
RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE, OLD QUEEN BUILDING, SOMERSET AND GEORGE STREETS, NEW BRUNSWICK, NJ 08903 (1)
4,806,341 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration 99 1986
 
SCULLY SCOTT MURPHY & PRESSER, PC (1)
5,426,112 Growth regulation and related applications of opioid antagonists 72 1993
 
SIMON, DAVID L. (1)
6,103,258 Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics 38 1998
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1)
4,803,208 Opiate agonists and antagonists 46 1985
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4,806,543 Method and compositions for reducing neurotoxic injury 68 1986
 
The Lynx Project Limited (1)
6,310,072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 38 1997
 
THE MCLEAN HOSPITAL CORPORATION (1)
5,075,341 Treatment for cocaine abuse 107 1989
 
The United States of America as represented by the Secretary of the Army (1)
5,834,477 Opiate analgesic formulation with improved safety 34 1994
 
United Biomedical, Inc. (1)
5,633,259 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 41 1995
 
Warner-Lambert Company (1)
5,149,538 Misuse-resistive transdermal opioid dosage form 129 1991
 
YOUNG, JACQUELINE, MS. (1)
5,356,900 Method of treating chronic herpes virus infections using an opiate receptor antagonist 46 1993
 
Other [Check patent profile for assignment information] (7)
4,464,378 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same 133 1981
4,443,428 Extended action controlled release compositions 75 1982
5,376,662 Method of attenuating nerve injury induced pain 44 1993
2004/0092,542 Tamper-resistant oral opioid agonist formulations 24 2003
2005/0095,291 Tamper-resistant oral opioid agonist formulations 34 2003
2005/0181,046 Tamper-resistant oral opioid agonist formulations 24 2003
2006/0039,970 Tamper-resistant oral opioid agonist formulations 15 2003

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (3)
8,518,925 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) 0 2005
8,105,631 Opioid agonist/antagonist combinations 3 2010
8,673,355 Opioid agonist/antagonist combinations 0 2011
 
Other [Check patent profile for assignment information] (1)
8,808,745 Morphine polymer release system 0 2013

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 6, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 6, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00